A non-randomized trial to assess the safety, tolerability, and pharmacokinetics of posaconazole oral suspension in immunocompromised children with neutropenia - Arrieta, Antonio C.; Sung, Lillian; Bradley, John S.; Zwaan, C. Michel; Gates, Davis; Waskin, Hetty; Carmelitano, Patricia; Groll, Andreas H.; Lehrnbecher, Thomas; Mangin, Eric; Joshi, Amita; Kartsonis, Nicholas A.; et al. (PloS one, 2019)
Keywords: Administration, Oral; Adolescent; Adults; Age; Age Factors; Antifungal agents; Antifungal Agents - administration & dosage; Antifungal Agents - adverse effects; Antifungal Agents - pharmacokinetics; Antineoplastic Agents; Area Under Curve; Biology and Life Sciences; Bone marrow; Cancer therapies; Chemotherapy; Child; Child, Preschool; Children; Dosage; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug dosages; Exposure; Female; Formulations; Fungal infections; Fungicides; Health aspects; Hospitals; Humans; Immunocompromised Host; Infant; Infection; Infectious diseases; Invasive Fungal Infections - drug therapy; Invasive Fungal Infections - immunology; Invasive Fungal Infections - prevention & control; Laboratories; Leukemia; Male; Medicine and Health Sciences; Mycoses; Neoplasms - drug therapy; Neutropenia; Neutropenia - chemically induced; Neutropenia - complications; Neutropenia - immunology; Oncology; Oral drugs; Pediatrics; People and Places; Pharmacokinetics; Pharmacology; Population; Posaconazole; Prophylaxis; Prospective Studies; Research and Analysis Methods; Safety; Steady state; Transplants & implants; Triazoles; Triazoles - administration & dosage; Triazoles - adverse effects; Triazoles - pharmacokinetics; Canada; Netherlands; United States--US; Germany